Luteolin-7-O-β-d-Glucuronide Attenuated Cerebral Ischemia/Reperfusion Injury: Involvement of the Blood–Brain Barrier
-
Published:2024-06-19
Issue:6
Volume:12
Page:1366
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Fan Xing1, Song Jintao2, Zhang Shuting2, Lu Lihui1, Lin Fang1, Chen Yu2, Li Shichang1, Jin Xinxin3, Wang Fang2ORCID
Affiliation:
1. School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China 2. School of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang 110016, China 3. Experimental Teaching Center of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, China
Abstract
Ischemic stroke is a common cerebrovascular disease with high mortality, high morbidity, and high disability. Cerebral ischemia/reperfusion injury seriously affects the quality of life of patients. Luteolin-7-O-β-d-glucuronide (LGU) is a major active flavonoid compound extracted from Ixeris sonchifolia (Bge.) Hance, a Chinese medicinal herb mainly used for the treatment of coronary heart disease, angina pectoris, cerebral infarction, etc. In the present study, the protective effect of LGU on cerebral ischemia/reperfusion injury was investigated in an oxygen–glucose deprivation/reoxygenation (OGD/R) neuronal model and a transient middle cerebral artery occlusion (tMCAO) rat model. In in vitro experiments, LGU was found to improve the OGD/R-induced decrease in neuronal viability effectively by the MTT assay. In in vivo experiments, neurological deficit scores, infarction volume rates, and brain water content rates were improved after a single intravenous administration of LGU. These findings suggest that LGU has significant protective effects on cerebral ischemia/reperfusion injury in vitro and in vivo. To further explore the potential mechanism of LGU on cerebral ischemia/reperfusion injury, we performed a series of tests. The results showed that a single administration of LGU decreased the content of EB and S100B and ameliorated the abnormal expression of tight junction proteins ZO-1 and occludin and metalloproteinase MMP-9 in the ischemic cerebral cortex of the tMCAO 24-h injury model. In addition, LGU also improved the tight junction structure between endothelial cells and the degree of basement membrane degradation and reduced the content of TNF-α and IL-1β in the brain tissue. Thereby, LGU attenuated cerebral ischemia/reperfusion injury by improving the permeability of the blood–brain barrier. The present study provides new insights into the therapeutic potential of LGU in cerebral ischemia.
Funder
Liaoning Provincial Livelihood Science and Technology Plan Project Scientific Research Project of the Education Department of Liaoning Province
Reference50 articles.
1. Zhao, X., Li, S., Mo, Y., Li, R., Huang, S., Zhang, A., Ni, X., Dai, Q., Wang, J., and Tu, W.-J. (2021). DCA Protects against Oxidation Injury Attributed to Cerebral Ischemia-Reperfusion by Regulating Glycolysis through PDK2-PDH-Nrf2 Axis. Oxidative Med. Cell. Longev., 2021. 2. Adipocyte fatty acid-binding protein exacerbates cerebral ischaemia injury by disrupting the blood-brain barrier;Liao;Eur. Heart J.,2020 3. Zhu, H., Hu, S., Li, Y., Sun, Y., Xiong, X., Hu, X., Chen, J., and Qiu, S. (2022). Interleukins and Ischemic Stroke. Front. Immunol., 13. 4. Srs11-92, a ferrostatin-1 analog, improves oxidative stress and neuroinflammation via Nrf2 signal following cerebral ischemia/reperfusion injury;Chen;CNS Neurosci. Ther.,2023 5. FCPR03, a novel phosphodiesterase 4 inhibitor, alleviates cerebral ischemia/reperfusion injury through activation of the AKT/GSK3β/ β-catenin signaling pathway;Xu;Biochem. Pharmacol.,2019
|
|